Vitreous-Retina-Macula Consultants of New York
New York, New York 10022
0 studies enrolling now · 17 studies all time
What they study most
AMD, AMD (With Persistent or Recurrent Fluid Despite Monthly Intravitreal Anti-VEGF Therapy), Age Related Macular Degeneration, Age-Related Macular Degeneration, CNV, Central Serous Chorioretinopathy, Choroidal Neovascularization, Fibrovascular Pigment Epithelial Detachment, Geographic Atrophy, Geographic Atrophy Secondary to Age-related Macular Degeneration, Macular Degeneration, Macular Neovascularization Secondary to Age-Related Macular Degeneration
Studies at this site
- An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD — Completed
- An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration — Running, not enrolling
- 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration — Running, not enrolling
- A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) — Completed
- Clinical Study to Evaluate Treatment With ORACEA® for Geographic Atrophy (TOGA) — Completed
- Clinical Validation of New OCT System — Completed
- Triton Fundus Autofluorescence and Fluorescein Angiography — Completed
- Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy — Completed
- Intense Treatment Regimen With Intravitreal Aflibercept Injection — Status unconfirmed
- To Evaluate The Role of Intravitreal Aflibercept Injection (2.0 mg) in the Management of Previously Treated Patients With Exudative AMD — Completed
- Open Label to Study to Evaluate Effect of Alfilbercept on Patients With (FVPED) Fibrovascular Pigment Epithelial Detachment — Withdrawn before enrolling
- A Pilot Study to Evaluate the Role of High-dose Ranibizumab (2.0mg) in the Management of AMD in Patients With Persistent/Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study) — Completed
- Use of Eylea for the Treatment of an Optic Nerve Hemangioma — NO_LONGER_AVAILABLE
- Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD — Completed
- Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration — Withdrawn before enrolling
- ICG-Guided Photodynamic Therapy for Treatment of Retinal Capillary Abnormalities: A Pilot Study — Status unconfirmed
- Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD — Stopped early